Bayer Updates Oral Contraceptive Labels

Share this article:

Bayer announced that it has updated the labels for its drospirenone-containing combination oral contraceptives (COCs) in the United States.

The updates include additional information from recent studies evaluating the risk of venous thromboembolism (blood clots) in women taking drospirenone-containing COCs.  It specifically states that these COCs may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing levonorgestrel or some other progestins. In addition, the revised labels update information that there is a risk of VTE among all COCs, but that the risk of VTE associated with pregnancy is even greater than the risk associated with any COC use, including drsp-containing COCs. 

Bayer's drospirenone-containing oral contraceptives include Yasmin, Yaz, and combination COCs Beyaz and Safyral (drospirenone, ethinyl estradiol and levomefolate calcium).

For more information call (800) 288-8371 or visit www.bayer.com.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

April Contest: Win a Pebble Watch

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs